Répertoire des subventions financées

Filtrer par

558 ésultat(s) trouvé(s)

Axonal degeneration as a therapeutic target for ALS

  • Type de programme

    Team grants

  • Disease Area

    ALS FR

  • Compétition

    Société canadienne de la SLA - Fondation Brain Canada - Bourses de découverte

  • Province

    Québec

  • Date de Début

    2023

  • Montant total du financement

    $300,000

  • Contribution Santé Canada

    $150,000

Aperçu du projet

One of the neuron’s most impressive morphological features is their long axonal projections, which are the basis of the complex, precise, and fast-firing neuronal network. To protect these fragile structures, neurons possess mechanisms to actively regulate axonal survival and degeneration, that are independent of the programmed cell death of the…

Modeling ALS progression by applying neuroinformatics to a novel in vitro human 3D tri-culture model of the disease

  • Type de programme

    Team grants

  • Disease Area

    ALS FR

  • Compétition

    Société canadienne de la SLA - Fondation Brain Canada - Bourses de découverte

  • Province

    Québec

  • Date de Début

    2023

  • Montant total du financement

    $125,000

  • Contribution Santé Canada

    $62,500

Aperçu du projet

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease in which the motor neurons degenerate, leading to symptoms of muscle weakness and progressive paralysis, resulting in the death of patients from respiratory failure. The development of disease modifying therapies have been largely unsuccessful due to the poor understanding into the mechanisms…

DNA damage driven motor disturbance in ALS: An ERVK integrase transgenic mouse model

  • Type de programme

    Team grants

  • Disease Area

    ALS FR

  • Compétition

    Société canadienne de la SLA - Fondation Brain Canada - Bourses de découverte

  • Province

    Manitoba

  • Date de Début

    2023

  • Montant total du financement

    $124,900

  • Contribution Santé Canada

    $62,450

Aperçu du projet

Endogenous retrovirus-K (ERVK) is a genomic viral symbiont that contributes towards ALS neuropathology. Our collaboration proposes to examine how ERVK integrase (IN) enzyme activity drives DNA damage, TDP-43 deregulation and neuronal loss, leading to motor disturbances using a novel ERVK IN transgenic mouse model system. The intent of this proposal…

Remote ischemic preconditioning treatment in amyotrophic lateral sclerosis

  • Type de programme

    Team grants

  • Disease Area

    ALS FR

  • Compétition

    Société canadienne de la SLA - Fondation Brain Canada - Bourses de découverte

  • Province

    Alberta

  • Date de Début

    2023

  • Montant total du financement

    $124,000

  • Contribution Santé Canada

    $62,000

Aperçu du projet

RATIONALE: There are no effective disease modifying therapies for amyotrophic lateral sclerosis (ALS). Complete understanding of the physiopathology of ALS is lacking, and single-target therapies have failed clinical translation. The overarching goal of this grant application is to test the hypothesis that remote ischemic preconditioning (REIP), a non-invasive, endogenous, pleiotropic…

Deepening our understanding of G3BP1 and its paralog G3BP2 to facilitate accurate therapeutic development for ALS/FTD

  • Type de programme

    Team grants

  • Disease Area

    ALS FR

  • Compétition

    Société canadienne de la SLA - Fondation Brain Canada - Bourses de découverte

  • Province

    Québec

  • Date de Début

    2023

  • Montant total du financement

    $125,000

  • Contribution Santé Canada

    $62,500

Aperçu du projet

While significant efforts have been made worldwide, the development of an effective therapy to significantly slow or halt ALS disease progression has remained elusive. This is due in part to our incomplete understanding of the molecular mechanisms and aberrant processes that lead to disease. TDP-43 (TAR DNA binding protein 43)…